Department of Neurosurgery, Center of Epilepsy, Beijing Institute for Brain Disorders, Beijing Key Laboratory of Epilepsy Research, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
Department of Brain Institute, Center of Epilepsy, Beijing Institute for Brain Disorders, Beijing Key Laboratory of Epilepsy Research, Sanbo Brain Hospital, Capital Medical University, Beijing, 100093, China.
CNS Neurosci Ther. 2023 Sep;29(9):2597-2607. doi: 10.1111/cns.14199. Epub 2023 Apr 5.
Deep brain stimulation (DBS) of the anterior nucleus of the thalamus, is an effective therapy for patients with drug-resistant epilepsy, yet, its mechanism of action remains elusive. Adenosine kinase (ADK), a key negative regulator of adenosine, is a potential modulator of epileptogenesis. DBS has been shown to increase adenosine levels, which may suppress seizures via A1 receptors (A Rs). We investigated whether DBS could halt disease progression and the potential involvement of adenosine mechanisms.
Control group, SE (status epilepticus) group, SE-DBS group, and SE-sham-DBS group were included in this study. One week after a pilocarpine-induced status epilepticus, rats in the SE-DBS group were treated with DBS for 4 weeks. The rats were monitored by video-EEG. ADK and A Rs were tested with histochemistry and western blot, respectively.
Compared with the SE group and SE-sham-DBS group, DBS could reduce the frequency of spontaneous recurrent seizures (SRS) and the number of interictal epileptic discharges. The DPCPX, an A R antagonist, reversed the effect of DBS on interictal epileptic discharges. In addition, DBS inhibited the overexpression of ADK and the downregulation of A Rs.
The findings indicate that DBS can reduce SRS in epileptic rats via inhibition of ADK and activation of A Rs. A Rs might be a potential target of DBS for the treatment of epilepsy.
丘脑前核深部脑刺激(DBS)是一种治疗耐药性癫痫患者的有效方法,但作用机制仍不清楚。腺苷激酶(ADK)是腺苷的关键负调节剂,也是癫痫发生的潜在调节剂。DBS 已被证明可以增加腺苷水平,通过 A1 受体(A Rs)抑制癫痫发作。我们研究了 DBS 是否可以阻止疾病进展以及腺苷机制的潜在参与。
本研究纳入了对照组、SE(癫痫持续状态)组、SE-DBS 组和 SE-sham-DBS 组。在匹鲁卡品诱导的癫痫持续状态后 1 周,SE-DBS 组的大鼠接受 DBS 治疗 4 周。通过视频-EEG 监测大鼠。分别通过组织化学和 Western blot 检测 ADK 和 A Rs。
与 SE 组和 SE-sham-DBS 组相比,DBS 可降低自发性复发性癫痫发作(SRS)的频率和间发性癫痫发作的次数。A R 拮抗剂 DPCPX 逆转了 DBS 对间发性癫痫发作的影响。此外,DBS 抑制了 ADK 的过度表达和 A Rs 的下调。
这些发现表明,DBS 通过抑制 ADK 和激活 A Rs 可以减少癫痫大鼠的 SRS。A Rs 可能是 DBS 治疗癫痫的潜在靶点。